{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"262","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"TTR: Defined for participants with confirmed objective response as time from first dose to first documentation of objective tumor response. sCR: complete response + normal FLC ratio \\& absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum\\& urine \\& disappearance of soft tissue plasmacytomas \\& \\<5% plasma cells in bone marrow aspirates. VGPR: serum\\& urine M-protein detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 hr. PR: \\>=50% reduction of serum M-protein\\& reduction in 24hrs urinary M-protein by \\>=90% or \\<200 mg/24hr. If serum \\& urine M-protein unmeasurable, \\>=50% decrease in difference between involved \\& uninvolved FLC levels required in place of M-protein criteria. Progression: Appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"MEDIAN","populationDescription":"mITT analysis set included all participants who have received at least one dose of study treatment. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)","title":"Part 2: TTR as Per IMWG Criteria","type":"SECONDARY","unitOfMeasure":"Days"}